Natriuretic Peptides, 6-Min Walk Test, and Quality-of-Life Questionnaires as Clinically Meaningful Endpoints in HF Trials

Journal of the American College of Cardiology

Volumn 68, Issue 24, 2016, Pages 2690-2707

  Ferreira, João Pedro ^a   Duarte, Kevin ^a   Graves, Todd L ^b   Zile, Michael R ^c   Abraham, William T ^d   Weaver, Fred A ^e   Lindenfeld, JoAnn ^f   Zannad, Faiez ^a  

^a UNIVERSITÉ DE LORRAINE   (France)

^b BERRY CONSULTANTS   (United States)

^c RALPH H JOHNSON VA MEDICAL CENTER   (United States)

^d OHIO STATE UNIVERSITY   (United States)

^e UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^f VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

heart failure trials; natriuretic peptides; surrogate endpoints

Indexed keywords

ALISKIREN; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BRAIN NATRIURETIC PEPTIDE; BUCINDOLOL; CANDESARTAN; CANRENONE; CARVEDILOL; DOBUTAMINE; ENALAPRIL; FERRIC CARBOXYMALTOSE; IVABRADINE; LEVOSIMENDAN; NATRIURETIC FACTOR; PLACEBO; ROSUVASTATIN; SACUBITRIL PLUS VALSARTAN; SERELAXIN; SPIRONOLACTONE; VALSARTAN; VERICIGUAT; BIOLOGICAL MARKER;

ACUTE HEART FAILURE; BAROREFLEX ACTIVATION THERAPY; CARDIAC RESYNCHRONIZATION THERAPY; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR PROCEDURE; DRUG DOSE COMPARISON; ENDURANCE TRAINING; EXERCISE TOLERANCE; HEART FAILURE; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART FAILURE WITH REDUCED EJECTION FRACTION; HOSPITAL READMISSION; HOSPITALIZATION; HUMAN; IRON DEFICIENCY; KANSAS CITY CARDIOMYOPATHY QUESTIONNAIRE; MINNESOTA LIVING WITH HEART FAILURE QUESTIONNAIRE; MORTALITY RATE; NEW YORK HEART ASSOCIATION CLASS; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; QUALITY OF LIFE ASSESSMENT; RESISTANCE TRAINING; REVIEW; SIX MINUTE WALK TEST; VAGUS NERVE STIMULATION; BLOOD; CLINICAL TRIAL (TOPIC); PROCEDURES; PSYCHOLOGY; QUESTIONNAIRE; WALK TEST;

BIOMARKERS; CLINICAL TRIALS AS TOPIC; HEART FAILURE; HUMANS; NATRIURETIC PEPTIDES; QUALITY OF LIFE; SURVEYS AND QUESTIONNAIRES; WALK TEST;

EID: 85004025739     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2016.09.936     Document Type: Review

References (88)

1. 1 Greene, S.J., Gheorghiade, M., Same protocol, different continents, different patients: should we continue to conduct global heart failure trials?. Eur J Heart Fail 17 (2015), 875–878.
2. 2 Food and Drug Administration. FDA-2014-D-0363: Expedited Access for Premarket Approval and De Novo Medical Devices Intended for Unmet Medical Need for Life Threatening or Irreversibly Debilitating Diseases or Conditions. 2015, Food and Drug Administration, Rockville, MD Available at: http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/UCM393978.pdf Accessed September 29, 2016.
3. 3 Masson, S., Latini, R., Anand, I.S., et al., Val-HeFT Investigators. Prognostic value of changes in N-terminal pro-brain natriuretic peptide in Val-HeFT (Valsartan Heart Failure Trial). J Am Coll Cardiol 52 (2008), 997–1003.
4. 4 Wessler, B.S., Kramer, D.G., Kelly, J.L., et al. Drug and device effects on peak oxygen consumption, 6-minute walk distance, and natriuretic peptides as predictors of therapeutic effects on mortality in patients with heart failure and reduced ejection fraction. Circ Heart Fail 4 (2011), 578–588.
5. 5 Seino, Y., Ogawa, A., Yamashita, T., et al. Application of NT-proBNP and BNP measurements in cardiac care: a more discerning marker for the detection and evaluation of heart failure. Eur J Heart Fail 6 (2004), 295–300.
6. 6 Groenning, B.A., Raymond, I., Hildebrandt, P.R., et al. Diagnostic and prognostic evaluation of left ventricular systolic heart failure by plasma N-terminal pro-brain natriuretic peptide concentrations in a large sample of the general population. Heart 90 (2004), 297–303.
7. 7 Maeda, K., Tsutamoto, T., Wada, A., et al. Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction. Am Heart J 135 (1998), 825–832.
8. 8 Kazanegra, R., Cheng, V., Garcia, A., et al. A rapid test for B-type natriuretic peptide correlates with falling wedge pressures in patients treated for decompensated heart failure: a pilot study. J Card Fail 7 (2001), 21–29.
9. 9 Kallistratos, M.S., Dritsas, A., Laoutaris, I.D., et al. N-terminal prohormone brain natriuretic peptide as a marker for detecting low functional class patients and candidates for cardiac transplantation: linear correlation with exercise tolerance. J Heart Lung Transplant 26 (2007), 516–521.
10. 10 Bettencourt, P., Azevedo, A., Pimenta, J., et al. N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients. Circulation 110 (2004), 2168–2174.
11. 11 Anand, I.S., Fisher, L.D., Chiang, Y.T., et al. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation 107 (2003), 1278–1283.
12. 12 Latini, R., Masson, S., Wong, M., et al. Incremental prognostic value of changes in B-type natriuretic peptide in heart failure. Am J Med 119 (2006), 70.e23–70.e30.
13. 13 Hartmann, F., Packer, M., Coats, A.J., et al. Prognostic impact of plasma N-terminal pro-brain natriuretic peptide in severe chronic congestive heart failure: a substudy of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial. Circulation 110 (2004), 1780–1786.
14. 14 Hartmann, F., Packer, M., Coats, A.J., et al. NT-proBNP in severe chronic heart failure: rationale, design and preliminary results of the COPERNICUS NT-proBNP substudy. Eur J Heart Fail 6 (2004), 343–350.
15. 15 Savarese, G., Musella, F., D'Amore, C., et al. Changes of natriuretic peptides predict hospital admissions in patients with chronic heart failure: a meta-analysis. J Am Coll Cardiol HF 2 (2014), 148–158.
16. 16 Cleland, J.G.F., Daubert, J.C., Erdmann, E., et al., Cardiac Resynchronization-Heart Failure (CARE-HF) Study Investigators. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 352 (2005), 1539–1549.
17. 17 Fruhwald, F.M., Fahrleitner-Pammer, A., Berger, R., et al. Early and sustained effects of cardiac resynchronization therapy on N-terminal pro-B-type natriuretic peptide in patients with moderate to severe heart failure and cardiac dyssynchrony. Eur Heart J 28 (2007), 1592–1597.
18. 18 Boccanelli, A., Mureddu, G.F., Cacciatore, G., et al., AREA IN-CHF Investigators. Anti-remodelling effect of canrenone in patients with mild chronic heart failure (AREA IN-CHF study): final results. Eur J Heart Fail 11 (2009), 68–76.
19. 19 Packer, M., McMurray, J.J.V., Desai, A.S., et al., PARADIGM-HF Investigators and Coordinators. Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. Circulation 131 (2015), 54–61.
20. 20 Gheorghiade, M., Böhm, M., Greene, S.J., et al., ASTRONAUT Investigators and Coordinators. Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial. JAMA 309 (2013), 1125–1135.
21. 21 Abraham, W.T., Zile, M.R., Weaver, F.A., et al. Baroreflex activation therapy for the treatment of heart failure with a reduced ejection fraction. J Am Coll Cardiol HF 3 (2015), 487–496.
22. 22 Cleland, J.G., Pellicori, P., Defining diastolic heart failure and identifying effective therapies. JAMA 309 (2013), 825–826.
23. 23 Ferreira, J.P., Girerd, N., Rossignol, P., et al. Geographic differences in heart failure trials. Eur J Heart Fail 17 (2015), 893–905.
24. 24 Jhund, P.S., Anand, I.S., Komajda, M., et al. Changes in N-terminal pro-B-type natriuretic peptide levels and outcomes in heart failure with preserved ejection fraction: an analysis of the I-Preserve study. Eur J Heart Fail 17 (2015), 809–817.
25. 25 Solomon, S.D., Zile, M., Pieske, B., et al., Prospective comparison of ARNI with ARB on Management Of heart failUre with preserved ejectioN fracTion (PARAMOUNT) Investigators. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet 380 (2012), 1387–1395.
26. 26 Logeart, D., Thabut, G., Jourdain, P., et al. Predischarge B-type natriuretic peptide assay for identifying patients at high risk of re-admission after decompensated heart failure. J Am Coll Cardiol 43 (2004), 635–641.
27. 27 Stienen, S., Salah, K., Dickhoff, C., et al. N-terminal pro-B-type natriuretic peptide (NT-proBNP) measurements until a 30% reduction is attained during acute decompensated heart failure admissions and comparison with discharge NT-proBNP levels: implications for in-hospital guidance of treatment. J Card Fail 21 (2015), 930–934.
28. 28 Mebazaa, A., Nieminen, M.S., Packer, M., et al., SURVIVE Investigators. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. JAMA 297 (2007), 1883–1891.
29. 29 Cohen-Solal, A., Logeart, D., Huang, B., et al. Lowered B-type natriuretic peptide in response to levosimendan or dobutamine treatment is associated with improved survival in patients with severe acutely decompensated heart failure. J Am Coll Cardiol 53 (2009), 2343–2348.
30. 30 Metra, M., Cotter, G., Davison, B.A., et al., RELAX-AHF Investigators. Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: correlation with outcomes. J Am Coll Cardiol 61 (2013), 196–206.
31. 31 Teerlink, J.R., Cotter, G., Davison, B.A., et al., RELAXin in Acute Heart Failure (RELAX-AHF) Investigators. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet 381 (2013), 29–39.
32. 32 Richards, A.M., Variability of NT-proBNP levels in heart failure: implications for clinical application. Heart 93 (2007), 899–900.
33. 33 Clerico, A., Zucchelli, G.C., Pilo, A., et al. Clinical relevance of biological variation of B-type natriuretic peptide. Clin Chem 51 (2005), 925–926.
34. 34 Zhang, F., Knoll, A., Systematic error modeling and bias estimation. Sensors (Basel), 16, 2016, 729.
35. 35 Bittner, V., Weiner, D.H., Yusuf, S., et al. Prediction of mortality and morbidity with a 6-minute walk test in patients with left ventricular dysfunction. JAMA 270 (1993), 1702–1707.
36. 36 Guyatt, G.H., Sullivan, M.J., Thompson, P.J., et al. The 6-minute walk: a new measure of exercise capacity in patients with chronic heart failure. Can Med Assoc J 132 (1985), 919–923.
37. 37 Olsson, L.G., Swedberg, K., Clark, A.L., et al. Six minute corridor walk test as an outcome measure for the assessment of treatment in randomized, blinded intervention trials of chronic heart failure: a systematic review. Eur Heart J 26 (2005), 778–793.
38. 38 Abraham, W.T., Young, J.B., Leon, A.R., et al. Effects of cardiac resynchronization on disease progression in patients with left ventricular systolic dysfunction, an indication for an implantable cardioverter-defibrillator, and mildly symptomatic chronic heart failure. Circulation 110 (2004), 2864–2868.
39. 39 Higgins, S.L., Hummel, J.D., Niazi, I.K., et al. Cardiac resynchronization therapy for the treatment of heart failure in patients with intraventricular conduction delay and malignant ventricular tachyarrhythmias. J Am Coll Cardiol 42 (2003), 1454–1459.
40. 40 Bristow, M.R., Saxon, L.A., Boehmer, J., et al., Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Investigators. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 350 (2004), 2140–2150.
41. 41 Young, J.B., Abraham, W.T., Smith, A.L., et al., Multicenter InSync ICD Randomized Clinical Evaluation (MIRACLE ICD) Trial Investigators. Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure: the MIRACLE ICD Trial. JAMA 289 (2003), 2685–2694.
42. 42 Cazeau, S., Leclercq, C., Lavergne, T., et al., Multisite Stimulation in Cardiomyopathies (MUSTIC) Study Investigators. Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay. N Engl J Med 344 (2001), 873–880.
43. 43 Abraham, W.T., Fisher, W.G., Smith, A.L., et al., MIRACLE Study Group. Cardiac resynchronization in chronic heart failure. N Engl J Med 346 (2002), 1845–1853.
44. 44 Gold, M.R., Van Veldhuisen, D.J., Hauptman, P.J., et al. Vagus nerve stimulation for the treatment of heart failure: the INOVATE-HF Trial. J Am Coll Cardiol 68 (2016), 149–158.
45. 45 Middlekauff, H.R., Making the case for skeletal myopathy as the major limitation of exercise capacity in heart failure. Circ Heart Fail 3 (2010), 537–546.
46. 46 Roul, G., Germain, P., Bareiss, P., Does the 6-minute walk test predict the prognosis in patients with NYHA class II or III chronic heart failure?. Am Heart J 136 (1998), 449–457.
47. 47 Hülsmann, M., Berger, R., Sturm, B., et al. Prediction of outcome by neurohumoral activation, the six-minute walk test and the Minnesota Living with Heart Failure Questionnaire in an outpatient cohort with congestive heart failure. Eur Heart J 23 (2002), 886–891.
48. 48 Dunlay, S.M., Manemann, S.M., Chamberlain, A.M., et al. Activities of daily living and outcomes in heart failure. Circ Heart Fail 8 (2015), 261–267.
49. 49 Auricchio, A., Stellbrink, C., Butter, C., et al., Guidant Heart Failure Research Group. Clinical efficacy of cardiac resynchronization therapy using left ventricular pacing in heart failure patients stratified by severity of ventricular conduction delay. J Am Coll Cardiol 42 (2003), 2109–2116.
50. 50 Toblli, J.E., Lombraña, A., Duarte, P., et al. Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency. J Am Coll Cardiol 50 (2007), 1657–1665.
51. 51 Tate, C.W. III, Robertson, A.D., Zolty, R., et al. Quality of life and prognosis in heart failure: results of the Beta-Blocker Evaluation of Survival Trial (BEST). J Card Fail 13 (2007), 732–737.
52. 52 Flynn, K.E., Piña, I.L., Whellan, D.J., et al., HF-ACTION Investigators. Effects of exercise training on health status in patients with chronic heart failure: HF-ACTION randomized controlled trial. JAMA 301 (2009), 1451–1459.
53. 53 O'Connor, C.M., Whellan, D.J., Lee, K.L., et al., HF-ACTION Investigators. Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial. JAMA 301 (2009), 1439–1450.
54. 54 Anker, S.D., Comin Colet, J., Filippatos, G., et al., FAIR-HF Trial Investigators. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 361 (2009), 2436–2448.
55. 55 Ponikowski, P., van Veldhuisen, D.J., Comin-Colet, J., et al., CONFIRM-HF Investigators. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. Eur Heart J 36 (2015), 657–668.
56. 56 Costanzo, M.R., Ivanhoe, R.J., Kao, A., et al. Prospective evaluation of elastic restraint to lessen the effects of heart failure (PEERLESS-HF) trial. J Card Fail 18 (2012), 446–458.
57. 57 Moss, A.J., Hall, W.J., Cannom, D.S., et al., MADIT-CRT Trial Investigators. Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med 361 (2009), 1329–1338.
58. 58 Veazie, P.J., Noyes, K., Li, Q., et al. Cardiac resynchronization and quality of life in patients with minimally symptomatic heart failure. J Am Coll Cardiol 60 (2012), 1940–1944.
59. 59 Pitt, B., Pfeffer, M.A., Assmann, S.F., et al., TOPCAT Investigators. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 370 (2014), 1383–1392.
60. 60 Lewis, E.F., Kim, H.Y., Claggett, B., et al., TOPCAT Investigators. Impact of spironolactone on longitudinal changes in health-related quality of life in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist trial. Circ Heart Fail, 9, 2016, e001937.
61. 61 Pfeffer, M.A., Claggett, B., Assmann, S.F., et al. Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial. Circulation 131 (2015), 34–42.
62. 62 Solomon, S.D., Clagget, B., Lewis, E.F., et al., TOPCAT Investigators. Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. Eur Heart J 37 (2016), 455–462.
63. 63 Shah, A.M., Claggett, B., Sweitzer, N.K., et al. Prognostic importance of impaired systolic function in heart failure with preserved ejection fraction and the impact of spironolactone. Circulation 132 (2015), 402–414.
64. 64 Shah, A.M., Claggett, B., Sweitzer, N.K., et al. Prognostic importance of changes in cardiac structure and function in heart failure with preserved ejection fraction and the impact of spironolactone. Circ Heart Fail 8 (2015), 1052–1058.
65. 65 Ypenburg, C., van Bommel, R.J., Borleffs, C.J., et al. Long-term prognosis after cardiac resynchronization therapy is related to the extent of left ventricular reverse remodeling at midterm follow-up. J Am Coll Cardiol 53 (2009), 483–490.
66. 66 Suzuki, H., Kusuyama, T., Omori, Y., et al. Inhibitory effect of candesartan cilexetil on left ventricular remodeling after myocardial infarction. Int Heart J 47 (2006), 715–725.
67. 67 Cicoira, M., Zanolla, L., Rossi, A., et al. Long-term, dose-dependent effects of spironolactone on left ventricular function and exercise tolerance in patients with chronic heart failure. J Am Coll Cardiol 40 (2002), 304–310.
68. 68 Konstam, M.A., Kramer, D.G., Patel, A.R., et al. Left ventricular remodeling in heart failure: current concepts in clinical significance and assessment. J Am Coll Cardiol Img 4 (2011), 98–108.
69. 69 McMurray, J.J.V., Packer, M., Desai, A.S., et al., PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 371 (2014), 993–1004.
70. 70 Lippi, G., Sanchis-Gomar, F., Monitoring B-type natriuretic peptide in patients undergoing therapy with neprilysin inhibitors. An emerging challenge?. Int J Cardiol 219 (2016), 111–114.
71. 71 Semenov, A.G., Katrukha, A.G., Different susceptibility of B-type natriuretic peptide (BNP) and BNP precursor (proBNP) to cleavage by neprilysin: the N-terminal part does matter. Clin Chem 62 (2016), 617–622.
72. 72 Bhatt, D.L., Mehta, C., Adaptive designs for clinical trials. N Engl J Med 375 (2016), 65–74.
73. 73 Saville, B.R., Connor, J.T., Ayers, G.D., et al. The utility of Bayesian predictive probabilities for interim monitoring of clinical trials. Clin Trials 11 (2014), 485–493.
74. 74 Berry, S.M., Connor, J.T., Lewis, R.J., The platform trial: an efficient strategy for evaluating multiple treatments. JAMA 313 (2015), 1619–1620.
75. 75 Saville, B.R., Berry, S.M., Efficiencies of platform clinical trials: a vision of the future. Clin Trials 13 (2016), 358–366.
76. 76 Wick, J., Berry, S.M., Yeh, H.W., et al. A novel evaluation of optimality for randomized controlled trials. J Biopharm Stat, 2016 Jun 13 [E-pub ahead of print] http://dx.doi.org/10.1080/10543406.2016.1198367.
77. 77 McKelvie, R.S., Yusuf, S., Pericak, D., et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure. Circulation 100 (1999), 1056–1064.
78. 78 Conraads, V.M., Beckers, P., Vaes, J., et al. Combined endurance/resistance training reduces NT-proBNP levels in patients with chronic heart failure. Eur Heart J 25 (2004), 1797–1805.
79. 79 Krum, H., Ashton, E., Reid, C., et al. Double-blind, randomized, placebo-controlled study of high-dose HMG CoA reductase inhibitor therapy on ventricular remodeling, pro-inflammatory cytokines and neurohormonal parameters in patients with chronic systolic heart failure. J Card Fail 13 (2007), 1–7.
80. 80 Pascual-Figal, D.A., Domingo, M., Casas, T., et al. Usefulness of clinical and NT-proBNP monitoring for prognostic guidance in destabilized heart failure outpatients. Eur Heart J 29 (2008), 1011–1018.
81. 81 Bielecka-Dabrowa, A., Goch, J.H., Mikhailidis, D.P., et al. The influence of atorvastatin on parameters of inflammation and function of the left ventricle in patients with dilated cardiomyopathy. Med Sci Monit 15 (2009), MS12–MS23.
82. 82 Zannad, F., De Ferrari, G.M., Tuinenburg, A.E., et al. Chronic vagal stimulation for the treatment of low ejection fraction heart failure: results of the NEural Cardiac TherApy foR Heart Failure (NECTAR-HF) randomized controlled trial. Eur Heart J 36 (2014), 425–433.
83. 83 Ordu, S., Yildiz, B.S., Alihanoglu, Y.I., et al. Effects of ivabradine therapy on heart failure biomarkers. Cardiol J 22 (2015), 501–509.
84. 84 Gheorghiade, M., Greene, S.J., Butler, J., et al., SOCRATES-REDUCED Investigators and Coordinators. Effect of vericiguat, a soluble guanylate cyclase stimulator, on natriuretic peptide levels in patients with worsening chronic heart failure and reduced ejection fraction: the SOCRATES-REDUCED Randomized Trial. JAMA 31 (2015), 2251–2262.
85. 85 Lipkin, D.P., Canepa-Anson, R., Stephens, M., et al. Factors determining symptoms in heart failure: comparison of fast and slow exercise tests. Br Heart J 55 (1986), 439–445.
86. 86 Guazzi, M., Dickstein, K., Vicenzi, M., et al. Six-minute walk test and cardiopulmonary exercise testing in patients with chronic heart failure: a comparative analysis on clinical and prognostic insights. Circ Heart Fail 2 (2009), 549–555.
87. 87 Täger, T., Hanholz, W., Cebola, R., et al. Minimal important difference for 6-minute walk test distances among patients with chronic heart failure. Int J Cardiol 176 (2014), 94–98.
88. 88 Ingle, L., Cleland, J.G., Clark, A.L., The relation between repeated 6-minute walk test performance and outcome in patients with chronic heart failure. Ann Phys Rehabil Med 57 (2014), 244–253.